FSHR and ovarian cancer: Antagonist of gonadotropin 10 and antibodies targeting surface-expressed FSHR 11-13 were shown the potential role of FSHR in ovarian cancer therapy, evident by suppression of tumorigenesis in mouse model of ovarian cancer.